12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Company News  |  Deals

Labopharm, Paladin deal

Paladin will acquire Labopharm for C$0.29 per share in cash, or C$20.4 million ($20.7 million) based on 71.6 million shares outstanding at Aug. 2. The price is a 68% premium to Labopharm's close of C$0.17 on Aug. 16, before the deal was announced. Paladin said the deal will strengthen its pain franchise and enhance international revenue. Paladin markets Abstral fentanyl in Canada to treat breakthrough cancer pain. Paladin has Canadian rights to the sublingual mucoadhesive fentanyl under a 2008 deal...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >